Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by Two Squalene Emulsion-Based Vaccine Adjuvants

Overview

Journal Vaccines (Basel)

Date 2024 May 25

PMID 38793782

Authors

Jayachandra Reddy Nakkala

Yibo Li

Labone Akter

Xinliang Kang

Xinyuan Chen

Affiliations

Soon will be listed here.

Abstract

MF59 and AS03 are squalene emulsion-based vaccine adjuvants with similar compositions and droplet sizes. Despite their broad use in licensed influenza vaccines, few studies compared their adjuvant effects and action mechanisms side by side. Considering the majority of adjuvants act on dendritic cells (DCs) to achieve their adjuvant effects, this study compared AddaVax and AddaS03 with similar compositions to MF59 and AS03 adjuvants to enhance antigen uptake, DC maturation, ovalbumin (OVA), and seasonal influenza vaccine-induced immune responses. Considering MF59 was reported to activate MyD88 to mediate its adjuvant effects, this study also investigated whether the above-explored adjuvant effects of AddaVax and AddaS03 depended on MyD88. We found AddaVax more potently enhanced antigen uptake at the local injection site, while AddaS03 more potently enhanced antigen uptake in the draining lymph nodes. AddaS03 but not AddaVax stimulated DC maturation. Adjuvant-enhanced antigen uptake was MyD88 independent, while AddaS03-induced DC maturation was MyD88 dependent. AddaVax and AddaS03 similarly enhanced OVA-induced IgG and subtype IgG1 antibody responses as well as influenza vaccine-induced hemagglutination inhibition antibody titers, whileAddaS03 more potently enhanced OVA-specific IgG2c antibody responses. Both adjuvants depended on MyD88 to enhance vaccine-induced antibody responses, while AddaVax depended more on MyD88 to achieve its adjuvant effects. Our study reveals similarities and differences of the two squalene emulsion-based vaccine adjuvants, contributing to our improved understanding of their action mechanisms.

Citing Articles

Correction: Nakkala et al. Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by Two Squalene Emulsion-Based Vaccine Adjuvants. 2024, , 531.

Nakkala J, Li Y, Akter L, Kang X, Chen X Vaccines (Basel). 2025; 12(12.

PMID: 39772113 PMC: 11680077. DOI: 10.3390/vaccines12121388.

References

Anderson 3rd D, Murphy K, Briseno C . Development, Diversity, and Function of Dendritic Cells in Mouse and Human. Cold Spring Harb Perspect Biol. 2017; 10(11). PMC: 6211386. DOI: 10.1101/cshperspect.a028613. View

Kim E, Woodruff M, Grigoryan L, Maier B, Lee S, Mandal P . Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway. Elife. 2020; 9. PMC: 7314549. DOI: 10.7554/eLife.52687. View

Jackson L, Campbell J, Frey S, Edwards K, Keitel W, Kotloff K . Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015; 314(3):237-46. DOI: 10.1001/jama.2015.7916. View

Shah R, Taccone M, Monaci E, Brito L, Bonci A, OHagan D . The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation. Sci Rep. 2019; 9(1):11520. PMC: 6687744. DOI: 10.1038/s41598-019-47885-z. View

Zhao Y, Li Z, Voyer J, Li Y, Chen X . Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development. ACS Appl Mater Interfaces. 2022; 14(19):21872-21885. PMC: 9121874. DOI: 10.1021/acsami.2c01028. View

Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S . The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci U S A. 2013; 110(52):21095-100. PMC: 3876261. DOI: 10.1073/pnas.1319784110. View

Li Z, Kang X, Kim K, Zhao Y, Li Y, Kang S . Effective adjuvantation of nanograms of influenza vaccine and induction of cross-protective immunity by physical radiofrequency adjuvant. Sci Rep. 2022; 12(1):21249. PMC: 9732352. DOI: 10.1038/s41598-022-25605-4. View

Calabro S, Tortoli M, Baudner B, Pacitto A, Cortese M, OHagan D . Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011; 29(9):1812-23. DOI: 10.1016/j.vaccine.2010.12.090. View

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V . Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29(13):2461-73. DOI: 10.1016/j.vaccine.2011.01.011. View

10.

Tegenge M, Von Tungeln L, Anderson S, Mitkus R, Vanlandingham M, Forshee R . Comparative pharmacokinetic and biodistribution study of two distinct squalene-containing oil-in-water emulsion adjuvants in H5N1 influenza vaccines. Regul Toxicol Pharmacol. 2019; 108:104436. DOI: 10.1016/j.yrtph.2019.104436. View

11.

Hauser M, Muscatello D, Soh A, Dwyer D, Turner R . An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines. Vaccine. 2019; 37(31):4246-4255. DOI: 10.1016/j.vaccine.2019.06.039. View

12.

Li Y, Li Z, Chen X . Comparative tissue proteomics reveals unique action mechanisms of vaccine adjuvants. iScience. 2023; 26(1):105800. PMC: 9813788. DOI: 10.1016/j.isci.2022.105800. View

13.

Lian Z, Okada T, He X, Kita H, Liu Y, Ansari A . Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol. 2003; 170(5):2323-30. DOI: 10.4049/jimmunol.170.5.2323. View

14.

Chen X . Emerging adjuvants for intradermal vaccination. Int J Pharm. 2022; 632:122559. PMC: 9794530. DOI: 10.1016/j.ijpharm.2022.122559. View

15.

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

16.

Winokur P, Hegmann T, Keitel W, Bernstein D, Frey S, Bryant C . Safety and Immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults. Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciac983. View

17.

Li Z, Zhao Y, Li Y, Chen X . Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines (Basel). 2021; 9(2). PMC: 7911902. DOI: 10.3390/vaccines9020075. View

18.

Yoshioka Y, Kobiyama K, Hayashi T, Onishi M, Yanagida Y, Nakagawa T . A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses α-tocopherol component. Front Immunol. 2023; 14:1116238. PMC: 9986537. DOI: 10.3389/fimmu.2023.1116238. View

19.

Li Z, Cao Y, Li Y, Zhao Y, Chen X . Vaccine delivery alerts innate immune systems for more immunogenic vaccination. JCI Insight. 2021; 6(7). PMC: 8119203. DOI: 10.1172/jci.insight.144627. View

20.

Stills Jr H . Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 2005; 46(3):280-93. DOI: 10.1093/ilar.46.3.280. View